Find information on thousands of medical conditions and prescription drugs.

Growth hormone deficiency

Growth hormone deficiency is the medical condition of inadequate production of growth hormone (GH) and its effects on children and adults. Growth hormone, also called somatotropin, is a polypeptide hormone which stimulates growth and cell reproduction. See separate articles on GH physiology and GH treatment. more...

Gardner's syndrome
Gastric Dumping Syndrome
Gastroesophageal reflux
Gaucher Disease
Gaucher's disease
Gelineau disease
Genu varum
Geographic tongue
Gerstmann syndrome
Gestational trophoblastic...
Giant axonal neuropathy
Giant cell arteritis
Gilbert's syndrome
Gilles de la Tourette's...
Gitelman syndrome
Glanzmann thrombasthenia
Glioblastoma multiforme
Glucose 6 phosphate...
Glycogen storage disease
Glycogen storage disease...
Glycogen storage disease...
Glycogenosis type IV
Goldenhar syndrome
Goodpasture's syndrome
Graft versus host disease
Graves' disease
Great vessels transposition
Growth hormone deficiency
Guillain-Barré syndrome

Deficiency of GH produces significantly different problems at various ages. In newborn infants the primary manifestations may be hypoglycemia or micropenis. In later infancy and childhood, growth failure may be major effect. Adults with growth hormone deficiency may have diminished lean body mass and poor bone density and a number of physical and psychological symptoms.

GH deficiency can be congenital or acquired in childhood or adult life. It can be partial or complete. It is usually permanent, but sometimes transient. It may be an isolated deficiency or occur in association with deficiencies of other pituitary hormones.

GH deficiency is treated by growth hormone replacement.


The term hypopituitarism is often used interchangeably with GH deficiency by endocrinologists but more often denotes GH deficiency plus deficiency of at least one other anterior pituitary hormone. When GH deficiency (usually with other anterior pituitary deficiencies) is associated with posterior pituitary hormone deficiency (usually diabetes insipidus) the condition is termed panhypopituitarism.

HGH also refers to human growth hormone but this older abbreviation has begun to develop paradoxical connotations (see fuller discussion of HGH in GH treatment and HGH quackery).

Causes of GH deficiency

There are many causes of GH deficiency. Some examples include:

  • mutations of specific genes (e.g., GHRHR, GH1)
  • congenital malformations involving the pituitary (e.g., septo-optic dysplasia, posterior pituitary ectopia)
  • damage to the pituitary from incracranial disease (e.g., hydrocephalus),
  • intracranial tumors in or near the sella turcica, especially craniopharyngioma,
  • damage to the pituitary from radiation therapy to the head for leukemia or brain tumors,
  • surgery in the area of the pituitary,
  • autoimmune inflammation (hypophysitis),
  • severe head trauma,
  • ischemic or hemorrhagic infarction from low blood pressure (Sheehan syndrome) or hemorrhage pituitary apoplexy.

Many cases of isolated growth hormone deficiency (IGHD) recognized in childhood are idiopathic. IGHD has been reported to affect about 1 in 4000 children, but IGHD is difficult to distinguish from other causes of shortness such as constitutional delay, and the true incidence is unsettled.

Severe prenatal deficiency of GH, as occurs in congenital hypopituitarism, has little effect on fetal growth. However, prenatal and congenital deficiency can reduce the size of a male's penis, especially when gonadotropins are also deficient. Besides micropenis, additional consequences of severe deficiency in the first days of life can include hypoglycemia and exaggerated jaundice (both direct and indirect hyperbilirubinemia). Female infants will lack the microphallus of course but may suffer from hypoglycemia and jaundice.


[List your site here Free!]

Undiagnosed Vitamin D deficiency in the hospitalized patient in the hospitalized patient
From American Family Physician, 1/15/05 by David Lyman

Patients with severe vitamin D deficiency and hypocalcemia present with classic findings of neuromuscular irritability, including numbness, paresthesias, muscle cramps, laryngospasm, Chvostek's sign, Trousseau's phenomenon, tetany, and seizures. (1) By contrast, patients with mild vitamin D deficiency present with more subtle complaints such as muscle weakness or pain. Finding only a modest reduction in a patient's calcium or phosphate level should not reassure the physician that all is well. When vitamin D deficiency is the cause of hypocalcemia or hypophosphatemia, replacing calcium or phosphate alone does not restore the body to homeostasis. (2,3)

Ionized hypocalcemia has been found in 15 to 50 percent of patients being treated in intensive care units (ICUs) and is associated with increased mortality and disease severity. (4,5) However, chronically ill patients only rarely develop true tetany and hemodynamic instability. (5,6)

Prolonged asymptomatic hypocalcemia from deficient vitamin D production or absorption stimulates the release of parathyroid hormone (PTH). If vitamin D is not provided, secondary hyperparathyroidism develops with increased bone turnover and decreased bone mineralization. (2) The adult patient with severe vitamin D depletion develops osteomalacia and presents with localized bone pain, antigravity muscle weakness, difficulty rising from a chair or walking, and pseudofractures. (3,7)

Illustrative Cases

Two hospitalized chronically ill patients with unrecognized vitamin D deficiency, hypocalcemia, and hypophosphatemia are presented below.


An elderly black woman was readmitted to the hospital from a nursing home because of progressive weakness. She had been discharged two weeks earlier following a four-month hospitalization for severe chronic obstructive pulmonary disease. During her previous hospital stay, she required prolonged mechanical ventilation through a tracheostomy tube and total, or central, parenteral nutrition (CPN). She was discharged to the nursing home on low-flow oxygen therapy. On readmission, she had a weak cough and required vigorous tracheal suctioning through her tracheostomy tube. Depressed levels of serum calcium and phosphate resistant to vigorous oral and intravenous replacement were noted on both hospital admissions. Before she was to return to the nursing home, her 25-hydroxyvitamin D level was 7 ng per mL (17 nmol per L; normal: 8 to 38 ng per mL [20 to 95 nmol per L]), and her PTH level was 161 pg per mL (17 pmol per L; normal: 9.5 to 49.4 pg per mL [1.0 to 5.2 pmol per L]). Vitamin D and calcium supplementation was to begin in the nursing home.


An elderly black man was transferred to the hospital from an extended-care facility because of progressive weakness, hypokalemia, and congestive heart failure. On admission, his potassium level was 2.2 mEq per L (2.2 mmol per L), digoxin was 1.6 ng per mL (2.0 nmol per L), magnesium was 1.1 mEq per L (0.55 mmol per L; normal: 1.3 to 2.0 mEq per L [0.65 to 1.00 mmol per L]), phosphorus was 2.3 mg per dL (0.74 mmol per L; normal: 2.5 to 4.5 mg per dL [0.81 to 1.45 mmol per L]), and calcium was 6.9 mg per mmol per dL (1.72 mmol per L; normal: 8.4 to 10.2 mg per dL [2.10 to 2.55 mmol per L]). He was in chronic atrial fibrillation with an ejection fraction of 12 percent and a therapeutic prothrombin time.

At the time of admission, he was diuresed and given potassium, magnesium, and calcium. Before discharge, the on-call physician noted that the patient's serum calcium and phosphorus levels were still low, and that his ionized calcium level was 3.9 mg per dL (0.97 mmol per L; normal: 4.5 to 5.3 mg per dL [1.12 to 1.32 mmol per L]). The patient was thin, dyspneic, and had a positive Chvostek's sign. The clinical diagnosis of vitamin D deficiency was made. Oral vitamin D supplementation was initiated in a dosage of 50,000 IU three times weekly.

One week after the patient was discharged from the hospital, the reference laboratory reported that his 25-hydroxyvitamin D level was 6 ng per mL (15 nmol per L). PTH levels were not obtained.

Risk Factors for Developing Vitamin D Deficiency

Vitamin D deficiency is common. The results of a 1998 study (8) reported a 57 percent prevalence of vitamin D deficiency in 290 patients admitted to a hospital in Massachusetts. The investigators found that assessment of common clinical risk factors through a multivariate model failed to identify many patients with vitamin D deficiency. (8)

The vitamin D-deficient patients presented in the two illustrative cases in this article were elderly, chronically ill, and malnourished with a poor vitamin D intake. Furthermore, these patients had no exposure to the sun. To produce a similar amount of vitamin D as persons with lightly pigmented skin, persons with darkly pigmented skin require three to six times more sun exposure. (7)

For the patient in case 1, the daily multivitamin supplement infused into the CPN provided only 200 IU of vitamin D (an amount thought to be adequate until recently). In 1997, based on the assumption that young and middle-aged adults were exposed to more sunlight than older adults, new dietary intakes of vitamin D were recommended as follows: 200 IU daily for children and adults 50 years and younger, 400 IU daily for adults 51 to 70 years of age, and 600 IU daily for adults older than 70 years. However, vitamin D supplementation was thought to have such a large margin of safety that 800 to 1,000 IU daily is not an unreasonable dose for all adults. (2,9,10)

Other disease states and characteristics not present in the illustrative cases but associated with the development of vitamin D deficiency include significant renal or hepatic disease, history of gastric resection or bypass, malabsorption, and use of certain medications such as anticonvulsants. (7) To remain normocalcemic, patients treated with phenytoin (Dilantin) or phenobarbital require two to five times the recommended daily amount of vitamin D. (3)

Vitamin D Metabolism and Physiology

Vitamin D is absorbed from the small intestine and is produced in the skin. Dietary vitamin [D.sub.2] comes from yeasts and plants; fish and cod-liver oil are good sources of vitamin [D.sub.3], which also is made in the skin. (3) In the skin, 7-dehydrocholesterol is converted to 3-cholecalciferol (or vitamin [D.sub.3]) after exposure to ultraviolet B radiation. (2,9) Vitamins [D.sub.2] and [D.sub.3] are equipotent in humans, and together are called "vitamin D." (3) Vitamins [D.sub.2] and [D.sub.3] are bound to the vitamin D-binding protein and transported to the liver, where 25-hydroxylation of vitamin D produces 25-hydroxyvitamin D, or calcidiol.

Calcidiol is the major circulating form of vitamin D. Although biologically inert, the 25-hydroxyvitamin D level most accurately reflects body stores. (2,3,9) Under the influence of PTH, 25-hydroxyvitamin D is further hydroxylated in the kidneys to 1,25-dihydroxyvitamin D or calcitriol, the hormonally active form of vitamin D. Calcitriol facilitates calcium absorption in the intestines and is required for the efficient utilization of dietary calcium. (3,10) 1,25-dihydroxyvitamin D also is thought to inhibit cellular growth, stimulate insulin secretion, and activate the immune system. (10)

The ICU patient with multiorgan failure has decreased hepatic production of 25-hydroxyvitamin D and reduced renal synthesis of 1,25-dihydroxyvitamin D. (3,4) PTH levels increase in response to decreasing 1,25-hydroxyvitamin D levels and impaired dietary calcium absorption. In the kidneys, PTH induces phosphaturia and increases tubular reabsorption of calcium. (2,7) High levels of PTH also activate osteoclasts in bone to provide essential calcium, resulting in osteopenia and osteoporosis. As both hypocalcemia and hypophosphatemia worsen, the calcium-phosphate product is no longer adequate to mineralize bone properly. Osteoblasts deposit a poorly mineralized collagen, a rubbery matrix that provides inadequate skeletal support. Painful osteomalacia (rickets, in children) is caused by the activation of periosteal sensory pain fibers deformed by weakened and poorly calcified bones. (10)

Diagnosis and Treatment


The findings of muscle weakness and pain on physical examination are nonspecific, and often are misdiagnosed as fibromyalgia. (10) The most sensitive test to diagnose vitamin D deficiency is the serum 25-hydroxyvitamin D level. (2,3,7) PTH levels are normal in early or mild vitamin D deficiency. (2) Only later do the findings of prolonged secondary hyperparathyroidism present (i.e., osteomalacia, osteoporosis).

If the vitamin D deficiency is mild (8 to 15 ng per mL [20 to 37 nmol per L]), patients should be given 800 IU of vitamin D with 1,500 mg of elemental calcium daily.2 Alternatively, serum 25-hydroxyvitamin D levels should increase from less than 15 ng per mL to 25 to 40 ng per mL (62 to 100 nmol per L) after eight weekly doses of 50,000 IU of vitamin D. With no additional vitamin D, adequate levels will be sustained for only two to four months. (3) Current recommendations are that patient levels be maintained above 32 ng per mL (80 nmol per L) to maximize bone health. (11)

In patients with severe vitamin D deficiency (serum levels of below 8 ng per mL with hypocalcemia), 50,000 IU of vitamin D should be given daily for one to three weeks, followed by weekly doses of 50,000 IU. (2,7) After repletion of body stores, 800 IU of vitamin D daily or 50,000 IU of vitamin D once or twice monthly is adequate maintenance therapy. (2,10) However, patients with no sun exposure or malabsorption, and those taking antiepileptic drugs may require larger maintenance doses of vitamin D (i.e., up to 50,000 IU one to three times weekly). (2,7) Table 1 (3,8,10) lists other treatment options.


In critically ill patients, albumin-adjusted calcium levels underestimate true or ionized hypocalcemia. Therefore, measured ionized calcium levels are recommended, particularly in patients who are being treated in an ICU. (12) Serum phosphate levels are elevated in most cases of hypocalcemia. However, patients deficient in vitamin D usually have low phosphate levels. Many disease processes can cause ionized hypocalcemia; Figure 1 (1-14) may help focus the evaluation.


Asymptomatic patients with ionized calcium levels higher than 3.2 mg per dL (0.8 mmol per L) can be closely monitored without therapy. Treatment can be considered if symptoms develop or the ionized calcium level falls below 3.2 mg per dL. (5) This cautious approach to calcium replacement is supported by a few case reports and animal studies that suggest mortality is increased when hypocalcemia is corrected in the setting of sepsis. (4,5,13)

There are no prospective studies on humans that support the use of calcium supplementation in asymptomatic ICU patients with hypocalcemia. (4) However, hypocalcemia should be aggressively corrected if the patient develops tetany, seizures, QT prolongation, bradycardia, or hypotension refractory to pressors, or in the mechanically ventilated patient where hypocalcemia is associated with decreased diaphragmatic function. (4,5)

Patients with severe or symptomatic hypocalcemia should be treated with intravenous calcium gluconate, which has 90 mg of elemental calcium in each 10-mL ampule and is less irritating to the veins than calcium chloride. (5) A bolus of 100 to 180 mg of elemental calcium given over five to 10 minutes will raise the calcium level for one to two hours. An infusion of 15 mg per kg of elemental calcium over four to six hours will increase the serum levels by 2 to 3 mg per dL (0.50 to 0.75 mmol per L). (5) Calcium levels should be checked every two to four hours, and serum calcium levels should be maintained in the low normal range. When calcium levels stabilize, oral supplementation should begin at a dosage of 1 to 4 g of elemental calcium daily. If calcium supplementation alone fails to maintain normal serum levels, the patient is vitamin D deficient or resistant and may benefit from a trial of calcitriol (Rocatrol). (5)


The patient described in case 1 required prolonged intubation and ventilatory support during her previous one-month hospitalization. Mechanical ventilation, theophylline, corticosteroids, and [beta.sub.2] agonists can cause hypophosphatemia. (14) Other causes of hypophosphatemia in the hospitalized patient include protein malnutrition, malabsorption, diabetic ketoacidosis, respiratory alkalosis, sepsis, antacid phosphate binders, and vitamin D deficiency. (6) Because hypophosphatemia and hypocalcemia decrease diaphragmatic function, serum calcium and phosphorous levels must be closely monitored in all patients who require mechanical ventilation. (13,14)

Symptoms of hypophosphatemia may range from fatigue and irritability to seizures and acute respiratory failure. (14) Mild hypophosphatemia (phosphate level higher than 1 mg per dL [0.50 mmol per L]) may be treated orally with sodium or potassium phosphate (e.g., Neutra-Phos-K, one packet twice daily). (6) In non-life-threatening situations (e.g., when using CPN) the patient may require 30 mmol per L or less per day of sodium or potassium phosphate for homeostasis. This is achieved by adding 2 mL of phosphate solution ([K.sub.2]P[O.sub.4]) to each liter of fluid given at 200 mL per hour. (14)

Severe hypophosphatemia (phosphate level below 0.5 mg per dL [0.15 mmol per L]) requires intravenous treatment with sodium or potassium phosphate. (6) In the critically ill patient, phosphorous is infused slowly to prevent tetany, hypotension, and hypocalcemia. 6,14 If the deficiency is severe, the patient will require 90 mmol per L in the first 24 hours: 6 mL of [K.sub.2]P[O.sub.4] is added to each liter of fluid and given at 200 mL per hour (1 mL of [K.sub.2]P[O.sub.4] is equal to 4 mEq of potassium and 3.0 mmol per L or 93 mg of phosphate). (14)

The safety of faster infusion rates (i.e., 15 to 45 mmol per L over one to three hours) has recently been demonstrated and may be preferred. (6) However, the vitamin D-depleted patient may present with refractory hypophosphatemia. In the absence of hypercalcemia or hypercalciuria, and after 25-hydroxyvitamin D levels have been drawn, the patient may benefit from a trial of calcitriol (0.25 to 0.50 mcg orally or via feeding tube) to decrease renal phosphate losses. (6)


(1.) Kapoor M, Chan GZ. Fluid and electrolyte abnormalities. Crit Care Clin 2001;17:503-29.

(2.) Thomas MK, Demay MB. Vitamin D deficiency and disorders of Vitamin D metabolism. Endocrinol Metab Clin North Am 2000;29:611-27.

(3.) Holick MF. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, D.C.: American Society for Bone and Mineral Research, 2003;129-37.

(4.) Carlstedt F, Lind L. Hypocalcemic syndromes. Crit Care Clin 2001;17:139-53.

(5.) Vasa FR, Molitch ME. Endocrine problems in the chronically critically ill patient. Clin Chest Med 2001;22:193208.

(6.) Mechanick JI, Brett EM. Endocrine and metabolic issues in the management of the chronically critically ill patient. Crit Care Clin 2002;18:619-41.

(7.) Yew KS, DeMieri PJ. Disorders of bone mineral metabolism. Clin Fam Pract 2002;4:525-65.

(8.) Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-83.

(9.) Nieves JW. Calcium, vitamin D, and nutrition in elderly adults. Clin Geriatr Med 2003;19:321-35.

(10.) Holick MF. Vitamin D deficiency: what a pain it is [editorial]. Mayo Clin Proc 2003;78:1457-9.

(11.) Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004;89:3152-7.

(12.) Slomp J, van der Voort PH, Gerritsen RT, Berk JA, Bakker AJ. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003;31:1389-93.

(13.) Pingleton SK. Nutrition in chronic critical illness. Clin Chest Med 2001;22:149-63.

(14.) Miller DW, Slovis CM. Hypophosphatemia in the emergency department therapeutics. Am J Emerg Med 2000;18:457-61.

DAVID LYMAN, M.D., M.P.H., is the medical director of the Greene Valley Developmental Center in Greeneville, Tenn. He received his medical degree and his master of public health degree from the University of Michigan Medical School, Ann Arbor. He completed a residency in family medicine at the University of Colorado Health Sciences Center, Denver, and a faculty development fellowship in family medicine at the University of North Carolina at Chapel Hill, Chapel Hill.

Address correspondence to David Lyman, M.D., M.P.H., Greene Valley Developmental Center, 4850 E. Andrew Johnson Hwy., Greeneville, TN 37744 (e-mail: Reprints are not available from the author.

The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Growth hormone deficiency
Home Contact Resources Exchange Links ebay